Cancer Family
Pleural Mesothelial Neoplasm
CI-CAN-00000322Explore in graph →
Non-malignant34 active trials4 approved drugs6 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000322Explore in graph →
Clinical trials
157 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers(REFIT-MSS) | withdrawn | Phase 2 | 0 | Translational Research in OncologyOTHER | 0 | Jun 7, 2023 | clinicaltrials |
| NCT03786419 | A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma | withdrawn | Phase 2 | 0 | Health Pharma Professional ResearchOTHER | 1 | May 13, 2021 |
| clinicaltrials |
| NCT04201145 | Pembrolizumab + Defactinib In Pleural Mesothelioma | withdrawn | Phase 1 | 0 | Raphael Bueno, MDOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT02661659 | A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy | withdrawn | Phase 1 | 0 | University of ChicagoOTHER | 1 | May 14, 2018 | clinicaltrials |
| NCT02639767 | Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma | withdrawn | Phase 1 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 7, 2016 | clinicaltrials |
| NCT01353482 | A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma(MESO-02) | withdrawn | Phase 1 / Phase 2 | 0 | University College, LondonOTHER | 0 | Mar 22, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Jun 7, 2023source: clinicaltrials